Reevaluation of the Usefulness of Systematic Bone Scanning in Initial Staging and follow-up of Small Cell Lung Carcinoma,Taking into Account the Serum Levels of Neuron-Specific Enolase
Restricted accessResearch articleFirst published online October, 1997
Reevaluation of the Usefulness of Systematic Bone Scanning in Initial Staging and follow-up of Small Cell Lung Carcinoma,Taking into Account the Serum Levels of Neuron-Specific Enolase
The prescription of bone scans (BS) in the initial staging and follow-up of small cell lung carcinoma (SCLC) is a traditional attitude. The availability of the serum neuron-specific enolase (NSE) assay and budget limitations led us to evaluate retrospectively, in 57 patients, the consequences of a more selective attitude, namely to perform BS only in those patients with abnormal serum NSE levels. Both BS and NSE assays were performed in 47 patients referred for initial staging of SCLC; NSE levels were normal in 8 but in 2 of these cases (25%) secondary bone localizations with great clinical significance were discovered at BS. During follow-up, 59 BS were performed in conjunction with NSE assays; 45 NSE levels were in the normal range whereas 17 (38%) corresponding BS were suggestive of bone metastases. In conclusion, due to the frequent occurrence of false-negative results in patients with bone metastases, serum NSE levels proved to be useless in the selection for BS of patients suffering from SCLC.
ThurlbeckW., ChurgM.Pathology of the lung.New York: Thieme Medical Publishers Inc, Stuttgart: Georg Thieme Verlag, 1995; 790–866.
2.
AdewoleI.F., NewlandsE.S.Neuron specific enolase as a tumour marker and comparative evaluation with carcinoembryonic antigen in small cell lung cancer.Med Oncol Tumor Pharmacother1987; 4(1): 11–5.
3.
AkounG.M., ScarnaH.M., MilleronB.J., BenichouM.P., HermanD.P.Serum neuron-specific enolase. A marker for disease extent and response to therapy for small-cell lung cancer.Chest1985; 87(1): 39–43.
4.
BorkE., HansenM., UrdalP.. Early detection of response in small cell bronchogenic carcinoma by changes in serum concentrations of creatinine kinase, neuron specific enolase, calcitonin, ACTH, serotonin and gastrin releasing peptide.Eur J Cancer Clin Oncol1988; 24(6): 1033–8.
5.
BuamahP.K., DrakeS.R., SmedleyH.M., BodgerW.A., SkillenA.W.Neuron-specific enolase during chemotherapy of small cell lung cancer.J Surg Oncol1990; 44(1): 1–4.
6.
BurghuberO.C., WorofkaB., SchernthanerG.. Serum neuron-specific enolase is a useful tumor marker for small cell lung cancer.Cancer1990; 65(6): 1386–90.
7.
CarneyD.N., MarangosP.J., IhdeD.C.. Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer.Lancet1982; 1(8272): 583–5.
CooperE.H., SplinterT.A., BrownD.A., MuersM.F., PeakeM.D., PearsonS.L.Evaluation of a radioimmunoassay for neuron specific enolase in small cell lung cancer.Br J Cancer1985; 52(3): 333–8.
10.
FischbachW., Schwarz-WallrauchC., JanyB.Neuron-specific enolase and thymidine kinase as an aid to the diagnosis and treatment monitoring of small cell lung cancer.Cancer1989; 63(6): 1143–9.
11.
GronowitzJ.S., BergstromR., NouE.. Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis.Cancer1990; 66(4): 722–32.
12.
HardingM., McAllisterJ., HulksG.. Neuron-specific enolase (NSE) in small cell lung cancer: a tumour marker of prognostic significance.Br J Cancer1990; 61(4): 605–7.
13.
JacquesG., BeplerG., HolleR.. Prognostic value of pretreatment carcinoembryonic antigen, neuron-specific enolase, and creatinine kinase-BB levels in sera of patients with small cell lung cancer.Cancer1988; 62(1): 125–34.
14.
JohnsonP.W., JoelS.P., LoveS.. Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer.Br J Cancer1993; 67(4): 760–6.
15.
JohnsonD.H., MarangosP.J., ForbesJ.T.. Potential utility of serum neuron-specific enolase levels in small cell carcinoma of the lung.Cancer Res1984; 44(11): 5049–14.
16.
JorgensenL.G., HansenH.H., CooperE.H.Neuron specific enolase, carcinoembryonic antigen and lactate dehydrogenase as indicators of disease activity in small cell lung cancer.Eur J Cancer Clin Oncol1989; 25(1): 123–8.
17.
JorgensenL.G., HirschF.R., SkovB.G., OsterlindK., CooperE.H., LarssonL.I.Occurrence of neuron specific enolase in tumour tissue and serum in small cell lung cancer.Br J Cancer1991; 63(1): 151–3.
18.
JorgensenL.G., OsterlindK., HansenH.H., CooperE.H.The prognostic influence of serum neuron specific enolase in small cell lung cancer.Br J Cancer1988; 58(6): 805–7.
19.
JorgensenL.G., OsterlindK., HansenH.H., CooperE.H.Serum neuron specific enolase (NSE) is a determinant of response duration in small cell lung cancer (SCLC).Br J Cancer1992; 66(3): 594–8.
20.
JorgensenL.G., OsterlindK., HansenH.H., CooperE.H.Serum neuron-specific enolase (S-NSE) in progressive small-cell lung cancer (SCLC).Br J Cancer1994; 70(4): 759–61.
21.
LehtinenM., WigrenT., LehtinenT.. Correlation between serum tumor marker levels and tumor proliferation in small cell lung cancer.Tumour Biology1988; 9(6): 287–92.
22.
LiippoK., TerhoT.Concomitant monitoring of serum neuron-specific enolase and creatine kinase BB in small cell lung cancer.Acta Oncologica1991; 30(3): 321–4.
23.
NouE., SteinholtzL., BerghJ., NilssonK., PahlmanS.Neuron-specific enolase, a follow up marker in small cell bronchial carcinoma: a prospective study in an unselected series.Cancer1990; 65: 1380–5.
24.
QuoixE., CharlouxA., PopinE., PauliG.Inability of serum neuron-specific enolase to predict disease extent in small cell lung cancer.Eur J Cancer1993; 29A(16): 2248–50.
25.
RapellinoM., PecchioF., ArosioC.. NSE and CEA determination in serum of patients with small cell lung cancer.J Nucl Med Allied Sciences1990; 34(4 Suppl): 147–9.
26.
SarandakouA., PoulakisN., RizosD., TrakakisE., PhocasI.Soluble interleukin-2 receptors (sIL-2R) and neuron specific enolase (NSE) in small cell lung carcinoma.Anticancer Res1993; 13(1): 173–5.
27.
SchmechelD., MarangosP.J., BrightmanM.Neuron-specific enolase is a molecular marker for peripheral and central neuroendocrine cells.Nature1978; 276: 834–6.
28.
SplinterT.A., CooperE.H., KhoG.S., OosteromR., PeakeM.D.Neuron-specific enolase as a guide to the treatment of small cel lung cancer.Eur J Cancer Clin Oncol1987; 23(2): 171–6.
29.
SplinterT.A., CooperE.H., OosteromR., PeakeM.D., BrownD.A., KhoG.S.Doubling time of neuron-specific enolase and survival in small cell lung cancer patients. Results of a preliminary analysis.Eur J Respiratory Dis1987; 149: 37–44.
30.
SplinterT.A., CarneyD.N., TeelingM., OosteromR.Levels of neuron-specific enolase after chemotherapy do not predict a response in small cell lung cancer.J Cancer Res Clin Oncol1988; 114(6): 641–3.
31.
SplinterT.A., CarneyD.N., TeelingM.. Neuron-specific enolase can be used as the sole guide to treat small-cell lung cancer patients in common clinical practice.J Cancer Res Clin Oncol1989; 115(4): 400–1.
32.
TapiaF.J., PolakJ.M., BarbosaA.J.A.. Neuron-specific enolase is produced by neuro-endocrine tumors.Lancet1981; 1: 808–11.
33.
Van de PolM., TwijnstraA., Ten VeldeG.P., MenheereP.P.Neuron-specific enolase as a marker of brain metastasis in patients with small-cell lung carcinoma.J Neuro-Oncol1994; 19(2): 149–54.
34.
Van der GaastA., Van PuttenW.L., OosteromR., CozijnsenM., HoekstraR., SplinterT.A.Prognostic value of serum thymidine kinase, tissue polypeptide antigen and neuron specific enolase in patients with small cell lung cancer.Br J Cancer1991; 64(2): 369–72.
35.
Van ZandwijkN., JassemE., BonfrerJ.M., Van TinterenH.Value of neuron specific enolase in early detection of relapse in small cell lung carcinoma.Eur J Cancer1990; 26(3): 373–6.
36.
PinsonP., JoosG., WatripontP., BrusselleG., PauwelsR.Serum neuron-specific enolase as a tumor marker in the diagnosis and follow-up of small-cell lung cancer.Respiration1997; 64(1): 102–7.
37.
LevensonR.M.Jr., SauerbrunnB.J., IhdeD.C., BunnP.A.Jr., CohenM.H., MinnaJ.D.Small cell lung cancer: radionuclide bone scans for assessment of tumor extent and response.Am J Roentgenol1981; 137(1): 31–5.
38.
LevitanN., ByrneR.E., BromerR.H.. The value of the bone scan and bone marrow biopsy in staging small cell lung cancer.Cancer1985; 56(3): 652–4.
39.
RescheI., BuheT., RogeC., BizaisY.Comparison of bone scintigram, MRI and osteomedullar biopsy in the detection of bone metastases in small cell lung cancer.J Nucl Med1992; 32: 962.
